Bailong Liu, Guodong Nie, Rui Luo, Junjie Liu, Yang Ding, Mengyu Liu, Zhong Fan, Min Liu, Xiaonan Pang
{"title":"老年ESCC患者联合免疫治疗的疗效及炎症标志物的预测作用。","authors":"Bailong Liu, Guodong Nie, Rui Luo, Junjie Liu, Yang Ding, Mengyu Liu, Zhong Fan, Min Liu, Xiaonan Pang","doi":"10.1080/20565623.2025.2564018","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the efficacy of immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy and evaluate the prognostic value of peripheral inflammatory markers in elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>A retrospective study of 124 elderly ESCC patients treated between 2021 and 2024. Patients were divided into immunotherapy and non-immunotherapy groups. Progression-free survival (PFS) was compared, and inflammatory markers were analyzed using Cox regression and ROC curves.</p><p><strong>Results: </strong>Median PFS was significantly longer in the ICI group (13.7 vs. 10.9 months, P = 0.043). Immunotherapy was an independent protective factor for PFS. Post-treatment NLR and PNI were predictive of outcomes in the ICI group.</p><p><strong>Conclusion: </strong>Combining ICIs with chemoradiotherapy improves survival in elderly inoperable ESCC patients. NLR and PNI may serve as accessible biomarkers to guide immunotherapy.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2564018"},"PeriodicalIF":2.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482436/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients.\",\"authors\":\"Bailong Liu, Guodong Nie, Rui Luo, Junjie Liu, Yang Ding, Mengyu Liu, Zhong Fan, Min Liu, Xiaonan Pang\",\"doi\":\"10.1080/20565623.2025.2564018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To assess the efficacy of immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy and evaluate the prognostic value of peripheral inflammatory markers in elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>A retrospective study of 124 elderly ESCC patients treated between 2021 and 2024. Patients were divided into immunotherapy and non-immunotherapy groups. Progression-free survival (PFS) was compared, and inflammatory markers were analyzed using Cox regression and ROC curves.</p><p><strong>Results: </strong>Median PFS was significantly longer in the ICI group (13.7 vs. 10.9 months, P = 0.043). Immunotherapy was an independent protective factor for PFS. Post-treatment NLR and PNI were predictive of outcomes in the ICI group.</p><p><strong>Conclusion: </strong>Combining ICIs with chemoradiotherapy improves survival in elderly inoperable ESCC patients. NLR and PNI may serve as accessible biomarkers to guide immunotherapy.</p>\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":\"11 1\",\"pages\":\"2564018\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482436/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20565623.2025.2564018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2025.2564018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients.
Aim: To assess the efficacy of immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy and evaluate the prognostic value of peripheral inflammatory markers in elderly patients with inoperable esophageal squamous cell carcinoma (ESCC).
Methods: A retrospective study of 124 elderly ESCC patients treated between 2021 and 2024. Patients were divided into immunotherapy and non-immunotherapy groups. Progression-free survival (PFS) was compared, and inflammatory markers were analyzed using Cox regression and ROC curves.
Results: Median PFS was significantly longer in the ICI group (13.7 vs. 10.9 months, P = 0.043). Immunotherapy was an independent protective factor for PFS. Post-treatment NLR and PNI were predictive of outcomes in the ICI group.
Conclusion: Combining ICIs with chemoradiotherapy improves survival in elderly inoperable ESCC patients. NLR and PNI may serve as accessible biomarkers to guide immunotherapy.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
